Physician profile
David H Good
NPI 1780009969
$1,826.26
in general payments reported to CMS, 2019-2025
28 companies · $378 in 2025
The $378 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.99 · 2020: $216 · 2021: $290 · 2022: $319 · 2023: $89.12 · 2024: $504 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $970.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $644.95 | 2020-2025 | Airsupra, Farxiga |
| Abbvie INC. | $150.79 | 2021-2025 | |
| Lilly USA, LLC | $127.03 | 2020-2024 | Mounjaro |
| Janssen Pharmaceuticals, INC | $95.02 | 2020-2023 | Spravato |
| Glaxosmithkline, LLC. | $86.99 | 2020-2024 | Trelegy Ellipta |
| Sk Life Science, INC. | $60.01 | 2021-2022 | |
| Pfizer INC. | $57.44 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $55.73 | 2022 | |
| Abbott Laboratories | $54.02 | 2021-2024 | Freestyle Libre 3 |
| Allergan, INC. | $47.55 | 2019-2020 | |
| Amgen INC. | $41.57 | 2020-2022 | |
| Amarin Pharma, INC. | $38.99 | 2021 | |
| Dexcom, INC. | $37.90 | 2024 | Dexcom G6 Transmitter |
| Ucb, INC. | $36.78 | 2020-2021 | |
| Novo Nordisk INC | $34.00 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mindray Ds USA, INC. | $33.87 | 2024 | Na Electrode,Indirect,International, Patient Monitor |
| Astellas Pharma US INC | $32.73 | 2022-2023 | Myrbetriq |
| Antares Pharma, INC. | $24.08 | 2025 | Xyosted |
| Alkermes, INC. | $22.28 | 2022 | |
| Convatec INC. | $19.47 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $18.50 | 2024 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.38 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.05 | 2022 | |
| Eisai INC. | $16.56 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.66 | 2025 | Xifaxan |
| Sanofi Pasteur INC. | $13.62 | 2023 | |
| Viatris Specialty LLC | $13.46 | 2025 | Yupelri |
| Melinta Therapeutics, LLC | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Good listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.